Drug intelligence / Profile preview

colulintide

Development stage: Phase 1
Lead developer: Eli Lilly
Modality: Peptides
Administration: Subcutaneous

Overview

**Colulintide (LY3541105)** is a synthetic peptide developed by Eli Lilly & Co. as a long-acting functional analog of amylin for the treatment of obesity. It acts as a dual agonist at the **amylin receptor (AMYR)** and **calcitonin receptor (CALCR)**, mimicking amylin's effects on appetite suppression, glucose control, and gastric emptying to promote weight loss. Administered subcutaneously, it reached Phase 1 trials for overweight/obesity but was discontinued.[1][2][4]

Other names: Colulintide

Targets

AMY receptor (Calcitonin receptor (with ramps))CALCR (Calcitonin receptor)

Beyond the preview

Go deeper on colulintide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on colulintide.